- Conditions
- Leukemia, Lymphoma
- Interventions
- bryostatin 1, fludarabine phosphate
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 3
- States / cities
- New York, New York • Philadelphia, Pennsylvania • Richmond, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 9,639
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
- Interventions
- laboratory biomarker analysis, pazopanib hydrochloride
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- CLN-619
- Drug
- Lead sponsor
- Cullinan Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
- Conditions
- Stage IV Breast Cancer
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2002
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Migraine
- Interventions
- Sounds
- Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Prolanta, a human prolactin receptor antagonist
- Biological
- Lead sponsor
- Oncolix, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Loncastuximab Tesirine, Mosunetuzumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
- Interventions
- Recombinant Fowlpox-TRICOM Vaccine, Recombinant Fowlpox GM-CSF Vaccine Adjuvant, Therapeutic Conventional Surgery, Pharmacological Study, Laboratory Biomarker Analysis
- Biological · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Relapsed/Refractory Aggressive B-Cell Lymphoma
- Interventions
- cemiplimab, odronextamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Leflunomide 10mg, Leflunomide 20mg, Decitabine
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Interventions
- UGN-301, UGN-201, Gemcitabine
- Drug
- Lead sponsor
- UroGen Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
- Conditions
- Healthy Subject, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer
- Interventions
- Computed Tomography, Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Magnetic Resonance Imaging
- Procedure · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
- Interventions
- GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
- Biological · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Disulfiram
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)
- Interventions
- Itacitinib, erlotinib, placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Ogden, Utah
- Conditions
- Advanced Cancers
- Interventions
- Questionnaires, Video, Fact Sheet
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cervical Cancer
- Interventions
- biopsy, computed tomography, positron emission tomography, fludeoxyglucose F 18
- Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
- Interventions
- Nivolumab, NKTR-214
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Up to 30 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • St Louis, Missouri
- Conditions
- Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- Carboplatin, Docetaxel
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Prostate Cancer
- Interventions
- fluciclovine (18F)
- Drug
- Lead sponsor
- Blue Earth Diagnostics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 6
- States / cities
- San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, CXCR1/2 Inhibitor SX-682, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography
- Procedure · Drug · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- O6-benzylguanine, temozolomide, conventional surgery
- Drug · Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer
- Interventions
- filgrastim, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody B3
- Biological · Procedure · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Squamous Cell Carcinoma of the Oropharynx
- Interventions
- ISA101b
- Drug
- Lead sponsor
- ISA Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Duarte, California • San Francisco, California • Aurora, Colorado + 5 more